

## **TSH Biopharm Co., Ltd. signed an exclusive regional market and joint development agreement for osteoporosis biosimilar drugs.**



TSH biopharm Co., Ltd. (8432) announced today (2/4) that it has recently obtained an exclusive osteoporosis biosimilar drug (code name: TRIAS) in a specific regional market and joint development agreement with an international pharmaceutical company. Si Yuan Yang, general manager of TSH biopharm Co., Ltd., pointed out that the drug has completed the clinical trials required for the investigation and is expected to be approved for marketing by the European Union EMA in the fourth quarter of this year. In addition to supplying the Taiwan market in the future, TRIAS also plans to expand to other countries. According to IQVIA's 2019 data, the global market size is about 1 billion U.S. dollars, and Taiwan is about 25 million U.S. dollars per year (about 700 million Taiwan dollars).

General Manager Si Yuan Yang explained in this cooperation case that TRIAS is mainly used to treat osteoporosis and is different from other osteoporosis drugs used to delay deterioration as the treatment target. TRIAS is one of the few products on the Taiwan market that targets osteoporosis. Its mechanism is that TRIAS and endogenous parathyroid hormone can be combined in the same receptor. Anabolic effects are manifested in the increase of bone mass and bone strength, thereby improving osteoporosis symptoms.

Osteoporosis is an essential topic of epidemiology. According to the World

Health Organization, osteoporosis is a vital disease second only to coronary heart disease globally, and it is also the fourth most common chronic disease in the elderly over 65 years old in Taiwan's National Health Agency. , There is a need for a high degree of treatment. TSH biopharm Co., Ltd. has exclusively obtained the right to market and joint development in a specific region this time, which means that TRIAS biosimilar drugs' product characteristics will bring considerable benefits to the treatment of patients.

General Manager Si Yuan Yang predicts that the product will be launched in Taiwan by the end of 2022 at the earliest. This will be the third drug of TSH biopharm Co., Ltd. goal of "three new drugs to be marketed in five years" from 2019, reaching the advanced deployment. Achievement. This joint development project will accelerate the advancement of the TRIAS joint development and listing process. It has completed the clinical trials required by the investigation and submitted them to the EMA for marketing authorization in Australia. TSH biopharm Co., Ltd. will continue to conduct studies or clinical trials for specific markets, create high Products with high quality, high similarity, high pharmacoconomics, and other characteristics that help patients, medical hospitals, and health insurance bureaus to achieve a win-win situation.

TSH Biopharm Co., Ltd. takes the "patient-centered" as the starting point through the "two-engine three-track advancement," with traditional pharmaceuticals and innovative medical treatment. Our central axis creates a medical product portfolio that focuses on providing patients with unmet needs. It is committed to new ingredients, unique formulations, chronic disease treatment, multiple genetic testing technologies, cancer detection, innovative therapies, cooperative development, and becoming the best partner of international innovative biopharmaceutical companies in developing and marketing new drugs in Asia. TSH Biopharm Co., Ltd. will contribute toward superior health with humans' life.

**Statement:** This press release and the related information released at the same time contain predictive statements; its content is judged and predicted based on existing risks and possible uncertainties, including market factors and other non- TSH biopharm Co., Ltd. (hereinafter referred to as The reason that the company can control. These predictive statements are based on predictions and assessments of the current situation; unless required by law, the company is not responsible for future updates.

**News report:**

- <https://reurl.cc/kVEaEr>
- <https://www.chinatimes.com/realtimenews/20210204004449-260418?chdtv>
- <https://www.chinatimes.com/realtimenews/20210205001722-260410?chdtv>
- <https://reurl.cc/Q7b4Rb>
- <https://reurl.cc/qmNkVD>
- <https://turnnewsapp.com/livenews/finance/@www.chinatimes.com--realtimenews--20210205001722-260410>
- <https://news.pchome.com.tw/finance/infotimes/20210205/index-16124898441478527003.html>
- <https://pchome.megatime.com.tw/m/news/cat2/20210205/16124898441478527003.html>
- <https://ctee.com.tw/livenews/aj/ctee/A89453002021020418354924>
- <https://www.chinatimes.com/realtimenews/20210204005454-260405?chdtv>
- <https://tw.appledaily.com/property/20210205/OMEGLFPEPVHKHCiQLQ75UKETY4/>
- <https://health.ltn.com.tw/article/breakingnews/3432431>
- <https://www.allnews.tw/news/18091>
- <https://www.moneydj.com/kmdj/news/newsviewer.aspx?a=06e65184-e9b2-48f9-bfd0-4ac1e506b6f7>
- <https://reurl.cc/Q7bZ4p>
- [https://www.biwennews.com/story.php?post\\_id=5420](https://www.biwennews.com/story.php?post_id=5420)